Background & Aims: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic
| INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease characterized by significant hepatic lipid deposition (steatosis). It affects 33% of the general population and up to 70-75% of diabetes and obese patients in Western countries. 1, 2 According to the "multiple hit" hypothesis, the insulin resistance plays a central role, by causing increased free fatty acid (FFA) flux to the liver, resulting in hepatic steatosis and lipotoxicity. 3, 4 The cross talk between dysfunctional adipocytes and liver involves combination of oxidative stress, inflammation, mitochondrial dysfunction and an imbalance of cytokines and adipokines, together with steatosis in development of lipotoxic liver disease, a term that more accurately describes the pathophysiology of non-alcoholic steatohepatitis (NASH). 4, 5 Reactive oxygen species, lipid peroxidation products and inflammation causes activation of hepatic stellate cells, leading to fibrosis and eventually cirrhosis and hepatocellular carcinoma. 3, 6 The lipotoxic liver injury hypothesis 4, 5 for the pathogenesis of NASH suggests that the ideal drug for NASH should reduce the burden of fatty acids going to the liver or being synthesized in the liver and this can be accomplished either by improving insulin sensitivity at the level of adipose tissue to prevent inappropriate peripheral lipolysis and/or by preventing unnecessary de novo lipogenesis in the liver.
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Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that play key roles in the regulation of metabolic homoeostasis, inflammation, cellular growth and differentiation. 7 The importance of dual PPARα and PPARγ agonists for the treatment of hypertriglyceridaemia and insulin resistance, respectively, is well established, but their role in the improvement of NAFLD/NASH remains unclear. In the liver, PPARα is expressed at high levels in hepatocytes and plays a major role in regulating fatty acid (FA) transport and β-oxidation. 8 PPARα also modulates inflammatory genes. 9 A protective role for PPARα against liver steatosis and inflammation in NASH has been suggested based on increased susceptibility of PPARα-knock out (KO) mice to NASH. 8 PPARγ agonists are strong insulin sensitizers. They regulate glucose and lipid metabolism 10 and have prominent anti-inflammatory activity. They prevent hepatic fibrogenesis in the liver by inhibiting the activation of hepatic stellate cells, which plays a key role in early phase of liver fibrosis. 11 Clinical studies with PPARγ in patients with NASH demonstrated improvements in insulin resistance and liver enzymes but showed variable effects on histological NASH features. 12, 13 In the light of the established beneficial roles of PPARα and γ in NAFLD and NASH, it is hypothesized that combined effect of PPARα 
| MATERIALS AND METHODS

| Chemicals
Saroglitazar ( Figure S1 ), pioglitazone and fenofibrate were synthesized by Cadila Healthcare Limited, Ahmedabad, India.
| Cell lines and treatments
HepG2 cells were maintained in DMEM supplemented with 10%
FBS and 100 U/mL penicillin/streptomycin (Invitrogen Carlsbad, CA, USA). Human hepatic stellate LX2 cells were maintained in DMEM with 5% FBS. The cells were maintained at 37°C and 5% RNA and protein were isolated using the methods described in
Supplementary Material Annexure I. The primer pair sequences used for Real-Time PCR Reactions for in vitro studies are listed in Table S1- A. The relative gene expression of fibrosis markers was quantified by qPCR from the mRNA obtained from HepG2-LX2 cells cocultured and 18S rRNA was used as housekeeping gene. Isolated proteins were subjected to immunoblotting with antibodies specific for anti-pNFkB and total NFkB (Cell Signaling Technology; dilution 1:1000). Densitometric analysis of the bands was performed by ImageJ software.
Key Points
• NAFLD & NASH are multifaceted conditions. The ideal drug for managing these conditions is expected to display beneficial effects on insulin resistance, steatosis, inflammation, oxidative stress, mitochondrial dysfunction and fibrosis.
• Beneficial roles of PPARα and γ in NAFLD and NASH are not clear.
• Saroglitazar, a dual PPARα/γ agonist demonstrated antisteatotic, anti-inflammatory effects along with alleviation of oxidative stress, mitochondrial dysfunction and fibrosis.
• 
| Animal experiments
The choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) model mimics human NASH by sequentially producing steatohepatitis, liver fibrosis and liver cancer without body weight loss. 16 Male C57BL/6 mice were housed in individually ventilated cages and maintained on a standard laboratory rodent diet, and were given CDAHFD (60 kcal% fat, Product #A06071302, from Research Diet, New Brunswick, NJ, USA, detail diet composition given in Table S4,) at 6 weeks of age for 20 weeks. The tissue distribution of saroglitazar was examined at T max and 24 hours post treatments in independent experiments performed in six male and six female Wistar rats after a single oral administration of saroglitazar (30 mg/kg). The levels of saroglitazar were estimated using LCMS-based method. All interventions occurred during the light cycle and more details are described in Data S1.
| Biochemical analysis
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and triglyceride (TG) levels were determined using commercial kits on a Cobas c311 autoanalyzer (Roche Diagnostics, Germany). The serum levels of monocyte chemoattractant protein1 (MCP1) were measured using a commercial Quantikine ELISA Kit supplied by R&D Systems, Inc., USA. Total liver lipids were extracted, and hepatic TG and total cholesterol (TC) content was quantified using triglyceride and total cholesterol test kits from Agappe Diagnostics, India. The liver TNFα, malondialdehyde (MDA) and collagen content levels were measured in tissue homogenates using BD OptEIA Mouse TNF ELISA kit (BD Biosciences, USA), QuantiChrom TBARS Assay Kit (BioAssays Systems Inc, USA) and total collagen assay kit (QuickZyme Biosciences,
The Netherlands) respectively; more details are described in Data S1.
| Histological assessment
Light microscopic examination of liver tissue was performed using F I G U R E 1 Lipid-mediated oxidative stress, inflammation and impaired mitochondrial biogenesis can be rectified upon saroglitazar treatment.
Results of cell viability in HepG2 cells treated with PA (0.75 mM) and various treatments for 16 h followed by MTT assay (A). The effect on mRNA levels of genes related to inflammation, mitochondrial biogenesis and antioxidants were measured using qPCR (B1, B2, B3). The cells were seeded into 60 mm dishes for flow cytometric analysis using the DCFDA dye specific for ROS generation (C). Immunoblotting was performed using phosphorylated and total NFkB and densitometric analysis was performed using ImageJ software (D). HepG2 cells were treated with PA (0.75 mM) and various treatments followed by measurement of oxygen consumption rate under basal respiratory conditions (E). The data were further used to calculate ATP production rate (F). Data are mean ± SEM. # P < .05 and ## P < .001 in comparison to control, *P < .05 and **P < .001 were considered significant in comparison to PA-group. CAT, catalase; GPX, glutathione peroxidase; IL, Interleukin; MFN-2, Mitofusin-2; NFKB, nuclear factor kappa-light-chain-enhancer of activated B cells; NRF-1, Nuclear respiratory factor 1; OPA, optic atrophy; SOD1, superoxide dismutase 1; TNFα, tumour necrosis factor α
Total NASH score was calculated by summation of all scores for the severity of hepatocellular steatosis, ballooning, inflammation and fibrosis by H&E staining for individual animals and then group mean ± SEM was calculated and effect of treatment was evaluated.
| Gene expression analysis
The expression of various genes was measured using Quantitative PCR (qPCR). The primer pair sequences used for real-time PCR reactions for in vivo studies are listed in Table S1 -B and detail of procedures followed up for RNA isolation, cDNA synthesis and Quantitative PCR (qPCR) are described in Data S1.
| Statistical analysis
In vitro experiment was performed at least three times in duplicate and data were analysed by one-way analysis of variance (ANOVA) followed by the post hoc test of Holm Sidak. # P < .05 and ## P < .001 indicates significant difference in comparison to control; *P < .05 and **P < .001
were considered significant in comparison to PA-group. For in vivo studies also data were analysed by ANOVA followed by the post hoc test of Holm Sidak. # indicates significant difference in control diet (Normal control) group vs Disease control, *P < .05; **P < .01 indicates significant difference vs CDAHFD + Vehicle Control (disease control) in test compound. All data are mean ± SEM. All data analysis was performed using GraphPad Prism software (GraphPad La Jolla California USA).
| RESULTS
| Saroglitazar treatment improves hepatocyte cell viability and rectifies lipid-mediated oxidative stress, inflammation and impaired mitochondrial biogenesis
HepG2 cells were treated with saroglitazar, fenofibrate, pioglitazone (Figure 1B3,D) . PA-induced mitochondrial fission led to reduced respiratory potential in mitochondria followed by reduced ATP production. Saroglitazar rescued the mitochondrial basal respiratory potential and improved the ATP production rate ( Figure 1E-F) . Interestingly pioglitazone and fenofibrate also were found to prevent toxic effects of PA, but overall beneficial effects of saroglitazar on cell viability, mitochondrial biogenesis makers and anti-inflammatory genes were significantly better than pioglitazone and was more largely comparable to fenofibrate. In this study, NASH was produced by feeding a CDAHF diet for 8 wk followed by the administration of a CDAHF diet for an additional 12 wk together with saroglitazar (3 mg/kg), pioglitazone (30 mg/kg. p.o.), fenofibrate (100 mg/kg) or vehicle treatment. Values are expressed as the means ± SEM of serum levels of various NASH biomarkers (n = 9). *P < .05; **P < .01 vs CDAHFD + Vehicle Control (disease control). #indicates control diet (Normal control) significance vs Disease control, P < .05.
upon saroglitazar and other drugs (Figure 2A) . Saroglitazar abrogated the formation of stress fibres in activated stellate cells as assessed by actin cytoskeletal reorganization by phalloidin staining more effectively than other drugs ( Figure 2B ).
| Saroglitazar displays liver-selective tissue distribution after oral administration
The tissue distribution of saroglitazar was determined in rats after a single oral administration. Blood and major organs were collected, and drug levels were measured. High concentrations of saroglitazar were measured in the liver at both the T max (0.67 hour) and 24-hour time points (Table S2) . At T max , the mean liver to plasma ratio was 4.40 for males and 4.99 for females. For the rest of the studied tissues, the ratio (tissue to plasma) was less than 1.0. The 24-hour samples also revealed drug concentrations with the potential for sustained effects.
| Saroglitazar reverses CDAHFD-induced NASH in C57BL/6 mice
The C57BL/6 mice that were maintained on CDAHFD for 8 weeks (Table 1) . These changes were accompanied by two-to three-fold increases in intrahepatic lipid (TG, TC) levels and four-fold increase in liver collagen content and two-fold increase in liver malondialdehyde levels ( Table 1 (Table 1) . Liver lipid (TG) accumulation and collagen content were also significantly (79% and 41% respectively) attenuated by saroglitazar treatment (Table 1) . Saroglitazar also showed the reduction in liver TNFα levels.
Fenofibrate treatment (100 mg/kg) also showed reductions in serum ALT, AST and MCP1, liver collagen content and MDA levels but there was no effect on TNFα levels of liver, whereas pioglitazone treatment showed reductions in serum ALT, MCP1 levels and liver MDA and TNFα levels but there was no effect on collagen content of liver;
however, the elevated liver lipids were not affected by either pioglitazone or fenofibrate treatment.
Saroglitazar has predominant PPARα activity, which explains the well-known and rodent-specific increase in liver weight observed in saroglitazar-and fenofibrate-treated mice but not in pioglitazonetreated animals. On the other hand, the epididymal fat mass increase, which is a PPARγ-mediated effect, was observed in saroglitazar-and pioglitazone-treated mice but not in fenofibrate-treated animals.
Microscopic examination of the liver sections after H&E staining revealed that saroglitazar (3 mg/kg) induced reversal of hepatic steatosis, reduced or no vacuolation and ballooning and there was significant reduction in the severity of inflammation ( Figure 3A) . Special stains for fat (Oil Red O, Figure 3B ), fibrosis (Masson's trichrome, Figure 3C ) and Kupffer cell accumulation (PAS-diastase, Figure 3D ) 
| DISCUSSION
Since NAFLD and NASH are multifaceted conditions, the ideal drug for managing these conditions is expected to display beneficial effects on insulin resistance, steatosis, inflammation, oxidative stress, mitochondrial dysfunction and fibrosis. Since, PPARα and PPARγ receptors are involved in regulation of all these attributes it is not surprising that saroglitazar, a dual PPAR agonist showed an overall improvement in NASH Score in CDAHFD-induced NASH model and results are correlated with in vitro observations.
The major biochemical event in NAFLD is the accumulation of triglycerides in hepatocytes. 6 PPARs are key regulators of lipid homoeostasis. 5 PPARα expression in the liver is primarily observed in hepatocytes, where its activation is expected to prevent steatosis and steatohepatitis by inhibiting intrahepatic lipid and lipoperoxide accumulation. 8, 9 On the other hand, PPARγ is predominantly observed in adipocytes, where its activation increases insulin sensitivity, 19 and thereby decreasing FA flux to the liver. Several lines of evidence suggest that impaired mitochondrial function is a central abnormality responsible for the progression from simple steatosis to steatohepatitis in NAFLD. 21 The results of in vitro study in HepG2 cells indicated that saroglitazar could recover the mitochondrial bioenergetics potential at both basal and stressed conditions and improved the ATP production rate. It is well known that target genes by unique engagement of PPAR co-activators and corepressors. 24 In the tissue distribution study, saroglitazar was found to be preferentially distributed in the liver, which may further explain the robust effect of saroglitazar on the liver. Our findings are also supported by telmisartan studies, an angiotensin receptor blocker which has shown a partial PPARγ activation and a PPARα agonistic activity in liver, improves non-alcoholic steatohepatitis in medaka NASH model.
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Studies performed with marketed PPARα agonists have demonstrated inconsistent effects on NAFLD/NASH. The PPARα agonist gemfibrozil has a favourable effect on liver enzymes, but fenofibrate showed variable results in several clinical trials. 26 The potential of PPARδ in NAFLD/NASH is also not clear. It is reported that adenovirusmediated hepatic PPARδ overexpression has been shown to activate de novo lipogenesis and subsequent lipid deposition. 27 Similarly, the PPARδ agonist GW501516, enhanced the fibrotic response. Since saroglitazar showed overall beneficial effects in the management of NAFLD and NASH in this study, it is likely that dual PPARα/γ agonism may be required for the treatment of NASH. It has been reported that saroglitazar has shown significant decrease in ALT levels in subjects with NAFLD and biopsy-proven NASH. 29 This study provides evidence in favour of saroglitazar as a candidate molecule for the management of NAFLD/NASH as it was found to improve all of the components that are responsible for these conditions. 
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